What is the recovery time after stem cell therapy for Heart Failure & Cardiac Repair?
Recovery and risk depend on the exact product, route and whether catheterisation is required, so a universal hospital-stay or improvement timeline is unsafe. Trial documents should describe administration, rhythm and haemodynamic monitoring, adverse-event and emergency arrangements, and follow-up. Patients must continue cardiologist-directed treatment; new chest pain, breathlessness, palpitations or syncope require urgent assessment.
What the evidence shows for Heart Failure & Cardiac Repair
Human heart-failure cell-therapy studies vary substantially by cell product, ischaemic or non-ischaemic cause, route, comparator and endpoint. Some studies report changes in imaging, exercise capacity or biomarkers, but consistent improvement in hospitalisation or survival has not been established for a marketed cell product. Exploratory subgroup findings should not be converted into a predictable response rate. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.
Am I a candidate? → · Heart Failure & Cardiac Repair: full overview → · Heart Failure & Cardiac Repair cost → · Cost →
Evidence checked against ISSCR, FDA and EMA guidance. See our editorial standards. This is information, not medical advice. Educational information, not medical advice; figures indicative.
Sources & further reading
More on this condition
- Heart Failure & Cardiac Repair: cell-therapy evidence and registered trials
- How much does stem cell therapy for Heart Failure & Cardiac Repair cost? (2026)
- Heart Failure & Cardiac Repair stem cell therapy — your questions answered (2026)
- Heart Failure & Cardiac Repair: cell-therapy evidence by therapy class
- MSC vs HSCT for Heart Failure & Cardiac Repair: what the registries show